A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Fulvestrant (Primary) ; Vistusertib (Primary) ; Everolimus
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MANTA
- 25 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2019.
- 25 Aug 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2019.
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.